Barinthus Biotherapeutics gets Nasdaq extension to Dec 28, 2026; listing moved to Capital Market

Barinthus Biotherapeutics plc.

Received 180-day extension from Nasdaq until Dec 28, 2026 to regain $1.00 minimum bid price for ADSs.
ADS listing transferred from Nasdaq Global Market to Nasdaq Capital Market effective July 2, 2026.
Company may consider reverse stock split to regain compliance; no assurance of success.
If bid price does not close at $1.00 for 10 consecutive days by Dec 28, 2026, ADSs may be delisted.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.